Abstract: The present invention includes an integrated system and methods for patient treatment, the system includes a hospital bed; a plurality of patient diagnostic and treatment devices connected to a network, wherein each of the devices can communicate to a network and exchange information with the network about the care of a patient; and a processor accessible adjacent to the bed and connected to the network to integrate information obtained from the devices through the network with one or more additional sources of information databases, wherein the processor can communicate to one or more patient treatment devices either directly or via the network and the processor directs the one or more patient treatment devices to change the treatment of the patient.
Type:
Application
Filed:
December 5, 2013
Publication date:
April 3, 2014
Applicant:
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Inventors:
John Michael DiMaio, James Watson, Jose Melendez, Roma Moza, Harry Tibbals
Abstract: The invention described herein pertains to compounds and compositions for treating Ape1 mediated diseases. In particular, the invention described herein pertains to quinone compounds and pharmaceutical compositions containing them for treating Ape1 mediated diseases.
Type:
Application
Filed:
May 25, 2012
Publication date:
April 3, 2014
Applicant:
INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION
Abstract: An integrated electron spin resonance (ESR) circuit chip includes a chip substrate, a transmitter circuit, and a receiver circuit. The transmitter circuit and receiver circuit are disposed on the chip substrate. The transmitter circuit includes an oscillator circuit configured to generate an oscillating output signal and a power amplifier (PA) circuit configured to generate an amplified oscillating output signal based on the oscillating output signal. The receiver circuit receives an ESR signal from an ESR probe. The receiver circuit includes a receiver amplifier circuit configured to generate an amplified ESR signal based on the received ESR signal, a mixer circuit configured to receive the amplified ESR signal and to down-convert the amplified ESR signal to a baseband signal, and a baseband amplifier circuit configured to generate an amplified baseband signal based on the baseband signal.
Type:
Application
Filed:
September 30, 2013
Publication date:
April 3, 2014
Applicant:
William Marsh Rice University
Inventors:
Xuebei Yang, Charles Chen, Payam Seifi, Aydin Babakhani
Abstract: A method of producing a monolithic ceramic body from a porous matrix includes providing a porous matrix having interstitial spaces, providing an infiltrating medium comprising a solvent and at least one reactive species, and infiltrating at least a portion of the interstitial space of the porous matrix with the infiltrating medium. The solvent is an inert medium that is not chemically reactive with the porous matrix, and is in a liquid phase when in the portion of the interstitial space of the porous matrix. The infiltrating medium is mechanically convected through the porous matrix. The at least one reactive species, when in a portion of the interstitial space of the porous matrix, reacts with a portion of the porous matrix to form a product, and the product fills at least a portion of the interstitial space.
Type:
Application
Filed:
September 30, 2013
Publication date:
April 3, 2014
Applicant:
Rutgers, The State University of New Jersey
Inventors:
Richard E. RIMAN, Vahit ATAKAN, John P. KUPPLER, Kenneth M. SMITH
Abstract: The present invention relates to a process for the removal of naphthenic acids from crude oils and crude oil distillates by use of supported basic ionic liquids.
Type:
Application
Filed:
November 23, 2011
Publication date:
April 3, 2014
Applicant:
The Queen's University of Belfast
Inventors:
Christopher Hardacre, Peter Goodrich, Azlan Hussain, David Rooney
Abstract: The present invention provides compounds and compositions that can modulate formation of Toll-like receptor 3 (TLR3) and double-stranded RNA (dsRNA) complex, and methods for using the same. In particular, some aspects of the invention provide compounds of the formula: compositions comprising and methods for using the same, where n, Ar1, Ar2, X1, X2, X3, Z1, and Z2 are those defined herein.
Type:
Application
Filed:
January 13, 2012
Publication date:
April 3, 2014
Applicant:
The Regents of the University of Colorado, a body corporate
Abstract: Biomarkers for diagnosis and prognosis of prostate cancer are provided. The biomarkers are promoter sequences have altered methylation patterns relative to normal prostate tissue. Altered expression of DNA methyltransferases (DNMT) and proteins that interact with DNMT result in increased methylation at a subset of prostate tumor hypermethylation sites.
Type:
Application
Filed:
April 2, 2012
Publication date:
April 3, 2014
Applicant:
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Inventors:
Gavin J. Sherlock, James Duane Brooks, Richard M. Myers, Yuya Kobayashi, Devin M. Absher
Abstract: Provided herein are inventive enopeptin compounds of Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Further provided are methods of preparation, use, and treatment.
Abstract: A method for making an epitaxial structure is provided. The method includes the following steps. A substrate having an epitaxial growth surface is provided. A buffer layer is formed on the epitaxial growth surface. A carbon nanotube layer is placed on the buffer layer. An epitaxial layer is epitaxially grown on the buffer layer. The substrate and the carbon nanotube layer are removed.
Type:
Application
Filed:
December 6, 2013
Publication date:
April 3, 2014
Applicants:
HON HAI PRECISION INDUSTRY CO., LTD., TSINGHUA UNIVERSITY
Abstract: Here provided is a method for regulating retinal endothelial cell viability in a mammal by administering to the mammal a therapeutically effective amount of a quinic acid analog. The method may be applied to prevent, treat or cure pathological conditions of retinal endothelial cells associated with radiation retinopathy, diabetic retinopathy and chemotherapy for retinoblastoma.
Type:
Application
Filed:
November 7, 2013
Publication date:
April 3, 2014
Applicant:
The University of Tennessee Research Foundation
Inventors:
Charles Ryan Yates, Jena Steinle Smith, Duane Douglas Miller, Jordan J. Toutounchian
Abstract: The present invention provides a method of detecting (e.g., by flow cytometry) a target compound, cell or particle, wherein the target is labelled with a detectable luminescent compound. The method comprises utilizing as the detectable luminescent compound a compound comprising a porphyrinic macrocycle such as a porphyrin, chlorin, bacteriochlorin, or isobacteriochlorin. In particular embodiments, the detectable luminescent compound comprises a compound of the formula A-A?-Z-B?-B, wherein: A is a targeting group or member of a specific binding pair that specifically binds the detectable luminescent compound to the target compound, cell or particle; A? is a linker group or covalent bond; B? is a linker group or covalent bond; B is a water-soluble group; and Z is the porphyrinic macrocycle.
Abstract: A combined teleoperative-cooperative controllable robotic system includes a robotic actuator assembly, a control system adapted to communicate with the robotic actuator assembly, and a teleoperation unit adapted to communicate with the control system. The control system is configured to control at least a first portion of the robotic actuator assembly in response to at least one of a force or a torque applied to at least a second portion of the robotic actuator assembly by a first user for cooperative control. The control system is further configured to control at least a third portion of the robotic actuator assembly in response to input by a second user from the teleoperation unit for teleoperative control.
Type:
Application
Filed:
September 28, 2012
Publication date:
April 3, 2014
Applicant:
The Johns Hopkins University
Inventors:
Russell H. TAYLOR, Marcin A. Balicki, Peter Kazanzides, Xia Tian
Abstract: A non-enteric coated pharmaceutical composition having an enhanced bioavailability comprising an acid-labile active ingredient and a nanolized biocompatible polymer, wherein the acid-labile active ingredient is mixed with and trapped by the nanolized biocompatible polymer, and the acid-labile active ingredient is sustainably released from the nanolized biocompatible polymer.
Abstract: An expression system, including a host cell, a synthetic spider silk polypeptide-encoding nucleotide sequence, at least one synthetic tRNA molecule-encoding nucleotide sequence or a synthetic serine hydroxymethyl transferase (SHMT)-encoding nucleotide sequence.
Type:
Application
Filed:
September 30, 2013
Publication date:
April 3, 2014
Applicant:
UTAH STATE UNIVERSITY
Inventors:
Randolph V. Lewis, Charles D. Miller, Asif Rahman, Cody Tramp, Michael Hinman
Abstract: The present invention relates to antibodies specific for a particular epitope on CD40 and antibodies that bind CD40 and have particular functional characteristics. The present invention also relates to fragments of these antibodies, uses of the antibodies for reduction or treatment of transplant rejection and graft-versus-host disease, and methods for making the antibodies.
Type:
Application
Filed:
March 12, 2012
Publication date:
April 3, 2014
Applicants:
EMORY UNIVERSITY, BETH ISRAEL DEACONESS MEDICAL CENTER INC
Inventors:
Keith A. Reimann, Rijian Wang, Christian P. Larsen
Abstract: An apparatus for acoustic or mechanical stimulation of a cochlea and measurement of acoustically or mechanically evoked electrophysiologic responses from the cochlea is provided. In one example, the apparatus includes an acoustic stimulator for generating an acoustic signal and an electrophysiologic response measuring device positioned proximal the cochlea or within the cochlea for measuring an acoustically evoked electrophysiologic response to the acoustic signal. Methods of utilizing the apparatus for diagnostic and therapeutic procedures related to hearing impairment are also provided.
Type:
Application
Filed:
July 24, 2013
Publication date:
April 3, 2014
Applicant:
THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
Abstract: Provided are engineered meat products formed as a plurality of at least partially fused layers, wherein each layer comprises at least partially fused multicellular bodies comprising non-human myocytes and wherein the engineered meat is comestible. Also provided are multicellular bodies comprising a plurality of non-human myocytes that are adhered and/or cohered to one another; wherein the multicellular bodies are arranged adjacently on a nutrient-permeable support substrate and maintained in culture to allow the multicellular bodies to at least partially fuse to form a substantially planar layer for use in formation of engineered meat. Further described herein are methods of forming engineered meat utilizing said layers.
Type:
Application
Filed:
November 27, 2013
Publication date:
April 3, 2014
Applicant:
The Curators Of the University of Missouri
Inventors:
Gabor FORGACS, Francoise MARGA, Karoly Robert JAKAB
Abstract: The disclosure relates to genetically modified swine wherein at least one allele of a SIGLEC1 gene has been inactivated and/or at least one allele of a CD163 gene has been inactivated. Genetically modified swine having both alleles of the SIGLEC1 gene and/or both alleles CD 163 gene inactivated are resistant to porcine reproductive and respiratory syndrome virus (PRRSV). Methods for producing such transgenic swine are also provided.
Type:
Application
Filed:
May 16, 2012
Publication date:
April 3, 2014
Applicant:
The Curators of The University of Missouri
Abstract: A device, system, and method for isolating a ventilator from one or more patients in which the delivery conditions of gas delivered to an isolation device from a ventilator may drive the delivery of breathing-gas delivered to one or more patients, the breathing-gas having the same or different delivery conditions. In one embodiment, an isolation device may have a housing and a movable partition. The movable partition may be joined to the housing, The movable partition may have a patient side on a first side of the partition and an actuating side on a second side of the partition. The isolation device may include an inlet pressure regulator on the actuating side and/or an exhaust pressure regulator on the patient side. These regulators may alter the delivery conditions (including, but not limited to, pressure and volume) of breathing-gas delivered to a patient.
Type:
Application
Filed:
December 9, 2013
Publication date:
April 3, 2014
Applicant:
The Research Foundation for the State University o
Abstract: A method for increasing the luminous efficacy of a white light emitting diode (WLED), comprising introducing optically functional interfaces between an LED die and a phosphor, and between the phosphor and an outer medium, wherein at least one of the interfaces between the phosphor and the LED die provides a reflectance for light emitted by the phosphor away from the outer medium and a transmittance for light emitted by the LED die. Thus, a WLED may comprise a first material which surrounds an LED die, a phosphor layer, and at least one additional layer or material which is transparent for direct LED emission and reflective for the phosphor emission, placed between the phosphor layer and the first material which surrounds the LED die.
Type:
Application
Filed:
December 6, 2013
Publication date:
April 3, 2014
Applicant:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Inventors:
Frederic S. Diana, Steven P. DenBaars, Shuji Nakamura